Human prion disease: molecular pathogenesis, and possible therapeutic targets and strategies
Authors:
Open Access
- 19 June 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 27 (12) , 1271-1284
Abstract
Human prion diseases are heterogeneous, and often rapidly progressive, transmissible neurodegenerative disorders associated with misfolded prion protein (PrP) aggregation and self-propagation. Despite their rarity, prion diseases comprise a broad spectrum of phenotypic variants determined at the molecular level by different conformers of misfolded PrP and host genotype variability. Moreover, they uniquely occur in idiopathic, genetically determined, and acquired forms with distinct etiologies. This review provides an up-to-date overview of potential therapeutic targets in prion diseases and the main results obtained in cell and animal models and human trials. The open issues and challenges associated with developing effective therapies and informative clinical trials are also discussed. Currently tested therapeutic strategies target the cellular PrP to prevent the formation of misfolded PrP or to favor its elimination. Among them, passive immunization and gene therapy with antisense oligonucleotides against prion protein mRNA are the most promising. However, the disease's rarity, heterogeneity, and rapid progression profoundly frustrate the successful undertaking of well-powered therapeutic trials and patient identification in the asymptomatic or early stage before the development of significant brain damage. Thus, the most promising therapeutic goal to date is preventing or delaying phenoconversion in carriers of pathogenic mutations by lowering prion protein expression.Keywords
Funding Information
- Ministry of Health (Ricerca corrente)
This publication has 136 references indexed in Scilit:
- Early Detection of Abnormal Prion Protein in Genetic Human Prion Diseases Now Possible Using Real-Time QUIC AssayPLOS ONE, 2013
- Healthy goats naturally devoid of prion proteinVeterinary Research, 2012
- Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected MiceMolecular Therapy Nucleic Acids, 2012
- Biological Effects and Use of PrP Sc - and PrP-Specific Antibodies Generated by Immunization with Purified Full-Length Native Mouse PrionsJournal of Virology, 2011
- Defining sporadic Creutzfeldt-Jakob disease strains and their transmission propertiesProceedings of the National Academy of Sciences, 2010
- Incidence and spectrum of sporadic Creutzfeldt–Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classificationActa Neuropathologica, 2009
- Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trialThe Lancet Neurology, 2009
- Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion diseaseProceedings of the National Academy of Sciences, 2008
- The Efficacy of Tetracyclines in Peripheral and Intracerebral Prion InfectionPLOS ONE, 2008
- Production of cattle lacking prion proteinNature Biotechnology, 2006